Nanocapsules: A novel lipid formulation platform for platinum-based anti-cancer drugs

Journal of Liposome Research

Volumn 17, Issue 3-4, 2007, Pages 183-189

  Hamelers, Irene H L ^a   De Kroon, Anton I P M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anti cancer drugs; Carboplatin; Cisplatin; Formulation technology; Improved cytotoxicity; Lipid formulation; Nanocapsules; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; LIPID; NANOCAPSULE; PLATINUM DERIVATIVE;

CONFERENCE PAPER; CYTOTOXICITY; DRUG FORMULATION; ENCAPSULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; TECHNOLOGY;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMISTRY, PHARMACEUTICAL; CISPLATIN; HUMANS; LIPIDS; NANOCAPSULES;

EID: 36249029986     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100701530290     Document Type: Conference Paper

References (35)

1. Akaboshi, M., Kawai, K., Maki, H., Akuta, K., Ujeno, Y., Miyahara, T. (1992). The number of platinum atoms binding to DNA, RNA, and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn. J. Cancer. Res. 83:522-526.
2. Andresen, T. L., Jensen, S. S., Jorgensen, K. (2005). Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog. Lipid. Res. 44:68-97.
3. Bandak, S., Goren, D., Horowitz, A., Tzemach, D., Gabizon, A. (1999). Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anti Canc. Drugs 10:911-920.
4. Bloemink, M. J., Reedijk, J. (1996). Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met. Ions Biol. Syst. 32:641-685.
5. Boulikas, T. (2004). Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol. Rep. 12:3-12.
6. Burger, K. N., Staffhorst, R. W., de Vijlder, H. C., Velinova, M. J., Bomans, P. H., Frederik, P. M., de Kruijff, B. (2002). Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med. 8:81-84.
7. Chupin, V., de Kroon, A. I., de Kruijff, B. (2004). Molecular architecture of nanocapsules, bilayer-enclosed solid particles of Cisplatin. J. Am. Chem. Soc. 126:13816-13821.
8. Connors, T. A., Jones, M., Ross, W. C., Braddock, P. D., Khokhar, A. R., Tobe, M. L. (1972). New platinum complexes with anti-tumour activity. Chem. Biol. Interact. 5:415-424.
9. Cooley, M. E., Davis, L. E., DeStefano, M., Abrahm, J. (1994). Cisplatin: a clinical review. Part I - Current uses of cisplatin and administration guidelines. Cancer Nurs. 17:173-184.
10. de Kroon, A. I., Staffhorst, R. W., de Kruijff, B., Burger, K. N. (2005). Cisplatin nanocapsules. Methods Enzymol. 391:118-125.
11. Dijt, F. J., Fichtinger-Schepman, A. M., Berends, F., Reedijk, J. (1988). Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48:6058-6062.
12. Douple, E. B. (1984). cis-Diamminedichloroplatinum(II): effects of a representative metal coordination complex on mammalian cells. Pharmacol Ther. 25:297-326.
13. el-Khateeb, M., Appleton, T. G., Gahan, L. R., Charles, B. G., Berners-Price, S. J., Bolton, A. M. (1999). Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques. J. Inorg. Biochem. 77:13-21.
14. Hamelers, I. H., van Loenen, E., Staffhorst, R. W., de Kruijff, B., de Kroon, A. I. (2006). Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol. Cancer Ther. 5:2007-2012.
15. Harrap, K. R. (1985). Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12 Suppl A:21-33.
16. Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., Peters, A. M., Stewart, J. S. (2001). Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 12:493-496.
17. Helleman, J., H., Burger, I. H., Hamelers, A. W., Boersma, A. I., de Kroon, G., Stoter, K., Nooter. (2006). Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol. Ther. 5:943-949.
18. Knox, R. J., Friedlos, F., Lydall, D. A., Roberts, J. J. (1986). Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1- cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46:1972-1979.
19. Ma, J., Verweij, J., Kolker, H. J., van Ingen, H. E., Stoter, G., Schellens, J. H. (1994). Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 and 20 h infusion. Br. J. Cancer. 69:858-862.
20. Meerum Terwogt, J. M., Groenewegen, G., Pluim, D., Maliepaard, M., Tibben, M. M., Huisman, A., ten Bokkel Huinink, W. W., Schot, M., Welbank, H., Voest, E. E., Beijnen, J. H., Schellens, J. M. (2002). Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 49:201-210.
21. Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., Amantea, M. A. (1999). Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43:1-7.
22. Papisov, M. I. (1998). Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions. Adv. Drug Deliv. Rev. 32:119-138.
23. Peleg-Shulman, T., Gibson, D., Cohen, R., Abra, R., Barenholz, Y. (2001). Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta 1510:278-291.
24. Reedijk, J. (2003). New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl. Acad. Sci. U S A. 100:3611-3616.
25. Riley, C. M., Sternson, L. A. (1985). Cisplatin. In Florey, K., ed. Analytical Profiles of Drug Substances. Vol. 14.. New York: Academic Press, pp. 78-105.
26. Schellens, J. H., Ma, J., Planting, A. S., van der Burg, M. E., van Meerten, E., de Boer-Dennert, M., Schmitz, P. I., Stoter, G., Verweij, J. (1996). Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer. 73:1569-1575.
27. Speelmans, G., Sips, W. H., Grisel, R. J., Staffhorst, R. W., Fichtinger-Schepman, A. M., Reedijk, J., de Kruijff, B. (1996). The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim. Biophys. Acta. 1283:60-66.
28. Speelmans, G., Staffhorst, R. W., Versluis, K., Reedijk, J., de Kruijff, B. (1997). Cisplatin complexes with phosphatidylserine in membranes. Biochemistry 36:10545-10550.
29. Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Deliconstantinos, G., Rigatos, S., Darli, E., Viliotou, V., Stathopoulos, J. G. (2005). Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol. Rep. 13:589-595.
30. Vail, D. M., Kurzman, I. D., Glawe, P. C., O'Brien, M. G., Chun, R., Garrett, L. D., Obradovich, J. E., Fred, 3rd, R. M., Khanna, C., Colbern, G. T., Working, P. K. (2002). STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother. Pharmacol. 50:131-136.
31. van der Vijgh, W. J. (1991). Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21:242-261.
32. Velinova, M. J., Staffhorst, R. W., Mulder, W. J., Dries, A. S., Jansen, B. A., de Kruijff, B., de Kroon, A. I. (2004). Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim. Biophys. Acta 1663:135-142.
33. Wang, D., Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4:307-320.
34. Wernyj, R. P., & Morin, P. J. (2004). Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist. Updat. 7:227-232.
35. Xiao, C., Qi, X., Maitani, Y., Nagai, T. (2004). Sustained release of cisplatin from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinoma. J. Pharm. Sci. 93:1718-1724.